Non-invasive assessment of cardiovascular risk and risk of diabetes

Clinically validated, convenient and easy to use

Advanced Glycation Endproducts play a key role in the development of chronic age-related diseases such as diabetes, renal failure and cardiovascular disease.

  • Harmfull compounds
  • Related to ageing
  • Glycaemic memory
  • Cardiovascular complications

Cardiovascular risk

CV risk assessment Cardiovasculair risk

It is critical to assess the individual cardiovascular risk of your patients. Finding high risk patients early allows doctors to adjust treatment as soon as possible.

  • Diabetes
  • Renal failure
  • Atherosclerosis
  • Other diseases
"AGE levels add new information for the development and progression of cardiovascular disease in both diabetic and non-diabetic patients, because AGE accumulation occurs before than glycated hemoglobin and more closely correlates with the severity of the disease, predicting the development of cardiovascular complications." Nenna et al (2015); Research in Cardiovascular Medicine
More Information
Request information

Would you like to learn more about our products? Request any information you wish to receive here.

Latest news

Vacancy Electronics Engineer

Groningen, the Netherlands - August 20, 2015 ......

» read more

The AGE Reader and Diab-spot have received approval in a number of countries. Please check with the distributor in your country or DiagnOptics what the regulatory approval status is in your country. US Caution: Federal law restricts the AGE Reader and Diab-spot system to investigational use only. Commercial distribution has not been granted by the US FDA. Please see the AGE Reader and Diab-spot user manuals for descriptions of all relevant warnings, cautions, contraindications and safety information.

About the company

Find information about DiagnOptics.

Information for patients

Find information about DiagnOptics' products and Advanced Glycation Endproducts.

Information for professionals

Find information about Advanced Glycation Endproducts, the AGE measurement and the clinical validation.